菜单

Locations

As a leading global CRDMO, with over 12,000 skilled employees in the United States, Ireland, Germany, China and Singapore, WuXi Biologics provides an extensive R&D and manufacturing network to support our clients worldwide.

United States
Massachusetts
U.S.
189,500sq.ft.
Capacity of36,000L
New Jersey
U.S.
154,400sq.ft.
Operations2021
Boston
U.S.
Research Service Center
Operational since2023
Ireland
Dundalk
Ireland
2.79 millionsq.ft.
Operations2022
Germany
Wuppertal
Germany
322,000sq.ft.
Operations2021
Singapore
Singapore
Integrated CRDMO center
Operational2026
China
Shanghai
Waigaoqiao Free Trade Zone
200,000sq.ft.
Operations2018
Shanghai
Fengxian District
1.6 millionsq.ft.
Operations2021
Shanghai
Lin-gang Special Area
86,000+sq.ft.
Operations2022
Wuxi
1.72 millionsq.ft.
Operations2012
Suzhou
170,000sq.ft.
Operations2014
Hangzhou
370,000sq.ft.
Operations2020
Chengdu
314,000sq.m.
Capacity of48,000L
Shijiazhuang
880,000sq.ft.
Operations2022
Hangzhou
530,000sq.ft.
Operations2021
Suzhou
123,000sq.ft.
Operations2017

World-class Quality

We provide quality assurance, quality control and operational systems that meet or exceed worldwide regulatory standards. Our premier world-class quality system have been approved by multiple global regulatory agencies for a wide variety of biologics and vaccines.

As of June 30, 2025
16

Facilities Certified for GMP Manufacturing

44

Successful Regulatory Inspections from 12 different Global Agencies

1700
+

Successful Global Client Audits

600
+

Successful Client INDs Filings

Sustainability

WuXi Biologics regards sustainability as the cornerstone of business development strategy, aligning it with our corporate vision and mission. We welcome our social and environmental responsibilities, and will continue to delivering a stronger ESG performance for all stakeholders and for the greater good of society.

Subscribe to our Newsletter

Stay up-to-date on our latest news, financial results and capabilities at our sites around the globe!

Latest News